Biotechnology valuation: an introductory guide
Author: Keegan, Karl D. Series: Wiley finance series Publisher: Wiley, 2008.Language: EnglishDescription: 206 p. : Graphs ; 25 cm.ISBN: 9780470511787Type of document: BookBibliography/Index: Includes bibliographical references and index and glossary
| Item type | Current location | Collection | Call number | Status | Date due | Barcode | Item holds |
|---|---|---|---|---|---|---|---|
|
Europe Campus Main Collection |
HC2000 .B5 K44 2008
(Browse shelf) 32419001248463 |
Available | 32419001248463 |
Includes bibliographical references and index and glossary
Digitized
Biotechnology Valuation An Introductory Guide Contents Acknowledgements 1 Introduction Biotechnology Background 2 Traditional Valuation Methods The Value of a Company Accounts -- Providing the Data for Valuation Analysis The Income Statement Balance Sheet Cash Flow Statement Income Statement Multiples Balance Sheet Multiples Summary Discounted Cash Flow Analysis Net Present Value Constructing the DCF Projecting the Cash Flow Stream Choosing a Discount Rate Other Thoughts 3 The Drug Development Process The Drug Development Process Drug Discovery and Research Pre-Clinical Development Clinical Trials What Investors Should Look For When Analysing Clinical Trials Conclusion The Regulatory Process Regulation in the US Regulation in Europe The Label xi 1 5 11 11 12 13 17 20 22 26 27 27 27 28 29 30 37 39 40 44 44 48 56 59 59 60 63 64 Timelines for Approval Post Approval Investment Lessons Case Study #1 4 Biotechnology Company Valuation Data Collation NPV of the Pipeline Calculations Sensitivity Analyses DCF of Whole Company EBIT DCF of Products Comparables Valuation NPVs are Additive Using all the Tools Available to Reach a Valuation Conclusion Market Models Conclusion Appendix 1 Example 1 Example 2 Example 3 Appendix 2 Biosimilar Update 5 Decision Trees and Real Options Decision Trees Discount Rate Deriving Scenarios Conclusion Decision Tree Example Real Options Valuing Options Estimation of the Input Variables Conclusions 6 Biotechnology Investing Types of Healthcare Investment Biotechnology Sector Evolution Biotechnology Investment Cycles Biotechnology Business Models Focus on People Cash Product Pipeline Commercial Risks Newsflow Lessons from Biotech Investing 65 65 66 66 69 71 75 80 86 92 97 99 101 101 104 105 106 106 108 108 116 116 119 120 124 125 125 126 126 129 138 139 141 141 143 145 152 154 155 155 156 158 160 7 Early-stage Valuation Private Valuation Discounted Cash Flow Method Comparable Valuation Venture Capital Method Discount Rates Conclusion Glossary References Index 161 162 166 168 170 173 173 175 189 193
There are no comments for this item.